Related Experiment Videos
A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia
Andrew C Dudley1, David Thomas, James Best
1Department of Medicine, St. Vincent's Hospital, University of Melbourne, Corner of Princes and Regent Streets, Fitzroy, VIC, 3065, Australia. andrew.dudley@childrens.harvard.edu
The Biochemical Journal
|May 28, 2005
Summary
Low oxygen activates the JAK2/STAT5 pathway in endothelial cells, crucial for angiogenesis in diseases like diabetic retinopathy and cancer. This pathway promotes cell survival by inhibiting apoptosis, aiding tumor growth and retinal neovascularization.
Area of Science:
- Endothelial cell biology
- Molecular signaling
- Vascular biology
Background:
- Oxygen homeostasis is critical for tissue survival.
- Diseases like diabetic retinopathy and cancer involve oxygen deprivation (hypoxia).
- Angiogenesis, the formation of new blood vessels, is a response to hypoxia.
Purpose of the Study:
- To investigate the role of the JAK2/STAT5 pathway in microvascular endothelial cells under low oxygen conditions.
- To understand the relationship between JAK2/STAT5 activation, VEGF, and apoptosis.
- To elucidate the significance of this pathway in pathological angiogenesis.
Main Methods:
- Cultured microvascular endothelial cells were exposed to hypoxic conditions.
- Activation of the JAK2/STAT5 pathway was assessed.
- The role of vascular endothelial growth factor (VEGF) was examined.
- Mechanisms of apoptosis regulation, including FAS/FASL, were investigated.
Main Results:
- Hypoxia activates the JAK2/STAT5 pathway in microvascular endothelial cells.
- This activation occurs downstream of VEGF signaling.
- Activated JAK2/STAT5 represses proapoptotic factors FAS and FASL.
- This leads to enhanced endothelial cell survival under hypoxic stress.
Conclusions:
- The JAK2/STAT5 pathway is a key mediator of endothelial cell survival during hypoxia.
- This pathway plays a critical role in tumor-associated and retinal angiogenesis.
- Targeting JAK2/STAT5 may offer therapeutic strategies for diseases involving pathological neovascularization.